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ABSTRACT 
 
 Rationale: The lysergamide lysergic acid diethylamide (LSD) is a prototypical classical 
hallucinogen with remarkably high potency.  LSD remains a popular recreational drug but is also 
becoming an important research tool for medical and neuroscience studies. Recently, several 
lysergamides that are close structural analogs of LSD have been sold as recreational drugs, 
which suggests that further studies are needed to explore the pharmacological properties of these 
compounds. Objective: In this present investigation, another LSD congener, N-ethyl-N-
cyclopropyl lysergamide (ECPLA), which to date has not been marketed as a recreational 
substance, was evaluated for its pharmacological features relative to those previously reported 
for LSD. The experiments focused on interactions with the 5-HT2A receptor, which is responsible 
for mediating the psychedelic effects of LSD and other hallucinogens. Methods: Competitive 
binding assays were performed to measure the affinity of ECPLA for 27 monoamine receptors. 
The ability of ECPLA to activate human 5-HT2 receptor subtypes was assessed using calcium 
mobilization assays.  Head twitch response (HTR) studies were conducted in C57BL/6J mice to 
determine whether ECPLA activates 5-HT2A receptors in vivo.  Two other N-alkyl substituted 
lysergamides, N-methyl-N-isopropyl lysergamide (MIPLA) and N-methyl-N-propyl lysergamide 
(LAMPA), were also tested in the HTR paradigm for comparative purposes. Results: ECPLA has 
high affinity for most serotonin receptors, α2-adrenoceptors, and D2-like dopamine receptors. 
Additionally, ECPLA was found to be a potent, highly efficacious 5-HT2A agonist for Gq-
mediated calcium flux. Treatment with ECPLA induced head twitches in mice with a median 
effective dose (ED50) of 317.2 nmol/kg (IP), which is ~40% of the potency observed previously 
for LSD.  LAMPA (ED50 = 358.3 nmol/kg) was virtually equipotent with ECPLA in the HTR 
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paradigm whereas MIPLA (ED50 = 421.7 nmol/kg) was slightly less potent than ECPLA. 
Conclusions: These findings demonstrate that the pharmacological properties of ECPLA, 
MIPLA and LAMPA are reminiscent of LSD and other lysergamide hallucinogens.      
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INTRODUCTION 
 
 (+)-Lysergic acid diethylamide (LSD; Figure 1) is one of the most potent serotonergic 
hallucinogens, with typical oral doses ranging from 60–200 µg (Shulgin and Shulgin 1997).  The 
activity of LSD is closely tied to the specific structure of its diethylamide moiety, and even 
minor modifications produce a dramatic reduction of potency.  Replacement of the diethylamide 
group of LSD with another alkylamide group or a cycloalkylamide moiety generally reduces 
hallucinogenic potency by at least an order of magnitude (Rothlin 1957; Murphree et al. 1958; 
Abramson 1959; Isbell et al. 1959; Abramson and Rolo 1967).  Even N-methyl-N-propyl 
lysergamide (LAMPA, MPLA or LMP-55), an isomer of LSD with similar hydrophobicity, is 
markedly less potent (Abramson and Rolo 1967). One exception is the conformationally 
restricted LSD analog (2′S,4′S)-lysergic acid 2,4-dimethylazetidide (LSZ), which retains high 5-
HT2A affinity and potency in rodent behavioral models (Nichols et al. 2002; Brandt et al. 2017a).  
 Although very few clinical investigations were carried out with LSD during the past few 
decades, numerous studies have been published in recent years.  Some of these investigations 
were conducted to assess potential therapeutic applications (Gasser et al. 2014,2015), but most 
studies were intended to assess the subjective response to LSD (Schmid et al. 2015; Carhart-
Harris et al. 2016a; Dolder et al. 2015,2016; Schmid and Liechti 2017) or to evaluate its 
neurophysiological effects (Carhart-Harris et al. 2016b; Tagliazucchi et al. 2016; Müller et al. 
2017a,b; Schmidt et al. 2017).  Thus, LSD is rapidly becoming an important tool in medical 
research.  
 There has been considerable interest in the pharmacology of LSD due to its high potency.  
LSD has been found to have high affinity for most serotonin (5-hydroxytryptamine, 5-HT) 
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receptors and also interacts with dopaminergic and adrenergic receptors (Leysen 1989; Peroutka 
1994; Marona-Lewicka and Nichols 1995; Watts et al. 1995; Nichols et al. 2002; Rickli et al. 
2015).  The psychedelic effects of serotonergic hallucinogens are largely mediated by 5-HT2A 
receptor activation; blockade of the 5-HT2A receptor eliminates the subjective effects produced 
by LSD and other hallucinogens in humans (Vollenweider et al. 1998; Valle et al. 2016; Barrett 
et al. 2017; Kraehenmann et al. 2017; Preller et al. 2017).  A recent x-ray crystallography study 
of LSD bound into the 5-HT2B receptor, along with receptor kinetics studies and molecular 
dynamics simulations, revealed that extracellular loop 2, which connects the top of helix 4 with 
helix 5, folds over the LSD molecule after it binds, dramatically hindering its dissociation from 
the receptor (Wacker et al. 2017).  This “entrapment” of LSD within the receptor may at least 
partially account for the high potency and long duration of action of this molecule.  Nevertheless, 
pharmacokinetic studies in humans indicate that the subjective effects of LSD occur in parallel 
with its presence in the body at effective concentrations (Dolder et al. 2015,2017). 
 LSD has been a popular recreational drug since the mid-1960s.  Although the use of LSD 
has occurred at relatively stable levels, in recent years several other lysergamides have been 
distributed as new psychoactive substances (NPS) or “research chemicals” (Brandt et al. 
2016,2017a,b,2018).  Most of the new lysergamides, including N6-allyl-6-norlysergic acid 
diethylamide (AL-LAD), N6-ethyl-6-norlysergic acid diethylamide (ETH-LAD), LSZ, and 
lysergic acid morpholide (LSM-775), were originally synthesized during the course of scientific 
research (Gogerty and Dille 1957; Hoffman and Nichols 1985; Nichols et al. 2002).  Other 
compounds, however, were specifically developed by NPS vendors as potential recreational 
drugs.  The lysergamides 1-propionyl-LSD (1P-LSD) and 1-propionyl-ETH-LAD (1P-ETH-
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LAD) were previously unknown in the scientific literature before they were marketed online as 
psychoactive substances (Brandt et al. 2016,2017b). 
 According to recent online postings, NPS vendors claimed to have synthesized N-ethyl-
N-cyclopropyl lysergamide (ECPLA; Figure 1), a novel lysergamide that is unknown in the 
scientific literature.  Therefore, we have compared the pharmacological properties of ECPLA to 
those previously reported for LSD.  Competitive binding assays were performed to measure the 
affinity of ECPLA for 27 monoamine receptors. Additionally, activation of 5-HT2 receptor 
subtypes by ECPLA was assessed using functional assays of Gq-coupled Ca2+-mobilization.   
 In addition to assessing whether ECPLA is likely to become a new recreational drug, 
another reason to investigate its pharmacology is to probe the structure-activity relationships 
governing the interactions between lysergamides and the 5-HT2A receptor.  Specifically, the 
studies were designed to test whether replacing one of the ethyl groups of LSD with a 
cyclopropyl substituent has a significant effect on 5-HT2A receptor affinity and potency.  The 
potency of LSD is significantly reduced by increasing the steric bulk of one of its amide 
substituents, as exemplified by N-ethyl-N-isopropyl lysergamide (EIPLA), which had three-fold 
lower affinity than LSD for 5-HT2A sites labeled with [3H]ketanserin in rat frontal cortex and 
almost 3-fold lower potency than LSD in the rat drug discrimination paradigm (Huang et al. 
1994).  However, it is not clear how potency would be affected by a marginal increase in steric 
bulk.  The steric bulk of a cyclopropyl group (with a calculated van der Waals volume of 43.8 
Å3) is more comparable to that of an ethyl group (VvdW = 38.9 Å3) compared to an isopropyl 
group (VvdW = 56.2 Å3; Zhao et al. 2003).   
  The head twitch response (HTR) is a rapid paroxysmal head movement induced by 
serotonergic hallucinogens in rats and mice due to 5-HT2A receptor activation (Canal and 
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Morgan 2012; Halberstadt and Geyer 2013).  The HTR is commonly used as a behavioral proxy 
in rodents for human hallucinogenic effects because it can reliably distinguish between 
hallucinogenic and non-hallucinogenic 5-HT2A receptor agonists (Gonzalez-Maeso et al. 2007).  
LSD and analogs such as AL-LAD and LSZ induce HTRs in mice with high potency (Corne and 
Pickering 1967; Halberstadt and Geyer 2013; Brandt et al. 2017a).  HTR studies were conducted 
in C57BL/6J mice to assess whether ECPLA activates 5-HT2A receptors and produces LSD-like 
behavioral effects in vivo.  To compare the potency of ECPLA with other N-alkyl-substituted 
lysergamides in mice, additional experiments examined the effect of N-methyl-N-isopropyl 
lysergamide (MIPLA) and LAMPA in the HTR paradigm.  These congeners have the same 
number of carbon atoms in the amide moiety and would have hydrophobicity virtually identical 
to LSD.  In addition, in rats trained to discriminate saline from LSD, MIPLA was only slight less 
potent than LSD (0.036 mg/kg vs 0.021 mg/kg, respectively).  Although MIPLA had 6-fold 
lower affinity than LSD at [3H]ketanserin-labeled sites in rat forebrain homogenate (28.1 vs. 4.78 
nM, respectively), it had about 82% of the affinity of LSD at [125I]DOI-labeled sites (MIPLA Ki 
= 1.75 nM, LSD Ki = 1.43 nM; Huang et al. 1994).  Importantly, MIPLA has been reported to 
have about one-third the potency of LSD as a psychedelic in man (Shulgin 2016).  Recent online 
postings indicate that MIPLA is available as an NPS (e.g., Anonymous, 2018).  By contrast, little 
is known about the pharmacology of LAMPA.  In a study conducted in six hallucinogen-
experienced subjects, administration of LAMPA (100 µg p.o.) had no effect in four subjects and 
produced effects consistent with a threshold dose of LSD in two subjects (Abramson and Rolo 
1967).    
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MATERIALS AND METHODS 
 
Animals 
 
 Male C57BL/6J mice (6-8 weeks old) obtained from Jackson Laboratories (Bar Harbor, 
ME, USA) were housed in a vivarium at the University of California San Diego, an AAALAC-
approved animal facility that meets all Federal and State requirements for care and treatment of 
laboratory animals. Mice were housed up to four per cage in a climate-controlled room on a 
reverse-light cycle (lights on at 1900 h, off at 0700 h) and were provided with ad libitum access 
to food and water, except during behavioral testing. Testing was conducted between 1000 and 
1800 h. All animal experiments were carried out in accordance with NIH guidelines and were 
approved by the UCSD animal care committee.  
 
Drugs 
 
 N-Ethyl-N-cyclopropyl lysergamide (ECPLA) was obtained from Synex Synthetics BV 
(Maastricht, The Netherlands) as the hemitartrate (2:1) salt.  N-Methyl-N-propyl lysergamide 
(LAMPA) was obtained from Lipomed Inc. (Cambridge, MA, USA) as the freebase.  N-Methyl-
N-isopropyl lysergamide (MIPLA) freebase was available from previous studies.  Competitive 
binding and functional assays were performed using ECPLA dissolved in dimethyl sulfoxide.  
For studies in mice, ECPLA was dissolved in isotonic saline and injected IP at a volume of 5 
mL/kg.  MIPLA and LAMPA were dissolved in 50 mM tartaric acid (pH ~5) and injected IP at 5 
mL/kg. 
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Binding Studies 
 
 A screening at 27 receptor binding sites was performed by the NIMH Psychoactive Drug 
Screening Program (NIMH PDSP).  ECPLA was tested at 10 µM in competition assays against 
radioactive probe compounds; each primary binding assay was performed in quadruplicate.  Sites 
exhibiting >50% inhibition at 10 µM were tested in secondary assays at the identified receptor 
using 11 concentrations of ECPLA, measured in triplicate, to generate competition binding 
isotherms.  Ki values were obtained from best-fit IC50 values (derived from nonlinear regression 
of the binding isotherms) using the Cheng-Prusoff equation (Cheng and Prusoff 1973).  The 
radioligands used were as follows: [3H]8-OH-DPAT (5-HT1A), [3H]GR125743 (5-HT1B/1D), 
[3H]5-HT (5-HT1E), [3H]ketanserin (5-HT2A), [3H]LSD (5-HT2B/5A/6/7), [3H]mesulergine (5-
HT2C), [3H]prazosin (α1A/1B/1D), [3H]rauwolscine (α2A/2B/2C), [125I]pindolol (β1), [3H]CGP12177 
(β2, β3), [3H]SCH23390 (D1, D5), [3H]N-methylspiperone (D2/3/4), [3H]pyrilamine (H1), 
[3H]tiotidine (H2), [3H]α-methylhistamine (H3), and [3H]histamine (H4).  The experimental 
protocols are available from the NIMH PDSP website (Roth 2013). 
 
5-HT2 Receptor Functional Assays 
 
 Detailed protocols for the functional assays have been published online (Roth 2013). 5-
HT2 functional experiments (measuring Gq-mediated calcium flux) were performed in HEK293 
cells stably expressing either human 5-HT2A, 5-HT2B, or 5-HT2C receptors.  The day before the 
assay, cells were seeded into poly-L-lysine-coated black 384-well clear-bottom tissue culture 
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plates with DMEM (Invitrogen, Carlsbad, CA, USA) containing 1% dialyzed fetal bovine serum 
at a density of ~15,000 cells in 40 µL per well.  The next day, a stock solution of ECPLA was 
diluted in assay buffer (HBSS, 20 mM HEPES, 2.5 mM probenecid, pH 7.4).  Media were 
decanted and replaced with 20 µL per well of assay buffer containing Fluo-4 Direct dye 
(Invitrogen) and incubated for 1 h at 37°C.  Plates were allowed to equilibrate at room 
temperature and Ca2+ flux was measured using a FLIPRTETRA system (Molecular Devices, 
Sunnyvale, CA, USA).  Plates were read for fluorescence initially for 10 s (1 read per s) to 
establish a baseline, and then stimulated by the addition of 10 µL/well of drug dilutions or buffer 
and read for an additional 120 s.  Peak fluorescence in each well was normalized to maximum-
fold increase over baseline.  Data were normalized to the maximum peak fold-over-basal 
fluorescence produced by 5-HT (100%) and baseline fluorescence (0%).  Data were analyzed 
using the sigmoidal dose-response function of GraphPad Prism 5.0. 
 
Head Twitch Response Studies 
 
 The head twitch response (HTR) was assessed using a head-mounted magnet and a 
magnetometer detection coil (Halberstadt and Geyer 2013,2014; Nichols et al. 2015; Klein et al. 
2018).  Briefly, mice were anesthetized, a small incision was made in the scalp, and a small 
neodymium magnet was attached to the dorsal surface of the cranium using dental cement.  
Following a two-week recovery period, HTR experiments were carried out in a well-lit room 
with at least 7 days between sessions to avoid carryover effects. Test compounds were injected 
immediately prior to testing.  Mice (n=5–7/group) were injected with drug or vehicle and then 
HTR activity was recorded in a glass cylinder surrounded by a magnetometer coil for 30 min.  
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Coil voltage was low-pass filtered (2–10 kHz cutoff frequency), amplified, and digitized (20 kHz 
sampling rate) using a Powerlab/8SP with LabChart v 7.3.2 (ADInstruments, Colorado Springs, 
CO, USA), then filtered off-line (40–200 Hz band-pass).  Head twitches were identified 
manually based on the following criteria: 1) sinusoidal wavelets; 2) evidence of at least three 
sequential head movements (usually exhibited as bipolar peaks) with frequency ≥ 40 Hz; 3) 
amplitude exceeding the level of background noise; 4) duration < 0.15 s; and 5) stable coil 
voltage immediately preceding and following each response.  
 
Data Analysis 
 
 Head twitch counts were analyzed using one-way analyses of variance (ANOVA).  Post 
hoc pairwise comparisons between selected groups were performed using Tukey's studentized 
range method.  Significance was demonstrated by surpassing an α-level of 0.05.  The entire 30-
min recordings were examined for head twitches, but in some cases a shorter block of time was 
used for analysis to accommodate compounds with a brief duration-of-action since potency 
calculations can be confounded by extended periods of inactivity.  Median effective doses (ED50 
values) and 95% confidence intervals (95% CI) for HTR dose-response experiments were 
calculated by nonlinear regression (Prism 7.00, GraphPad Software, San Diego, CA, USA).  A 
Gaussian distribution (Christopoulos et al. 2001) was used to fit biphasic HTR dose-response 
data: 
 
 E = Baseline+ Range × 𝑒! !"# [!]!!"#$!"#$% ! 
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 midA =  logED!" + slope −ln (0.5) 
 
In these equations, E is the drug effect, Baseline is the response in the control group, Range is 
the distance from Baseline to the top of the curve, [A] is the dose of the drug, and midA is the 
logarithm of the dose corresponding to the top of the curve. 
 
 
 
RESULTS 
 
 Table 1 lists the affinities of ECPLA for 27 serotonergic, adrenergic, dopaminergic, and 
histaminergic receptors.  The binding affinities and selectivity of ECPLA observed for 
monoaminergic sites are consistent with the values previously reported for LSD (Leysen 1989; 
Marona-Lewicka and Nichols 1995; Nichols et al. 2002; Rickli et al., 2015).  ECPLA was 
observed to bind nonselectively to 5-HT receptors with affinities in the 1–100 nM range.  The 
sites with the highest affinities were 5-HT1A (Ki = 3.2 nM), 5-HT2B (Ki = 5.3 nM), and 5-HT5A 
(Ki = 8.6 nM).  Using the same conditions, LSD was previously reported to bind to human 5-
HT2A receptors (labeled with [3H]ketanserin) and human 5-HT2C receptors (labeled with 
[3H]mesulergine) with Ki values of 13 nM and 30 nM, respectively (Nichols 2017); compared to 
LSD, ECPLA has equivalent affinity for the 5-HT2A receptor (Ki = 16.5 nM) but almost 3-fold 
lower affinity for the 5-HT2C receptor (Ki = 85.7 nM). ECPLA binds to α-adrenoceptors with 
some preference for α2 subtypes compared to α1A, α1B, and α1D sites.  The affinity of ECPLA for 
α2A and α2B adrenergic sites (Ki values of 144 nM and 62.3 nM, respectively) approximates the 
reported affinity of LSD for α2-adrenoceptors labeled with [3H]clonidine (Ki = 37–82 nM) in rat 
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cortex (Leysen 1989; Marona-Lewicka and Nichols 1995).  In contrast to LSD (Nichols et al. 
2002), ECPLA did not bind to β1 or β2 sites with appreciable affinity (<50% displacement at 10 
µM), but did interact with β3 sites with affinity in the micromolar range (Ki = 2,415 nM).  
Similar to LSD (Nichols et al. 2002; Rickli et al. 2015), ECPLA binds to dopamine receptors 
with some selectivity for D2-like sites (D2, D3, and D4 receptors) compared to D1-like sites (D1 
and D5 receptors).  ECPLA has negligible affinity for H1, H3, or H4 receptors in these 
experiments (i.e., <50% displacement at 10 µM), whereas it binds to H2 receptors with a Ki of 
890 nM.  LSD reportedly binds to H1 receptors with a Ki of 1,100 to 1,500 nM (Nichols et al. 
2002; Rickli et al. 2015) but its affinity for other histamine receptors has not been reported. 
 The effect of ECPLA on human 5-HT2A, 5-HT2B, and 5-HT2C receptors was assessed 
using Gq-mediated Ca2+ mobilization in HEK293 cells (Table 2).  As shown in Figure 2, ECPLA 
acted as a partial agonist at all three 5-HT2 receptor subtypes.  ECPLA has the highest potency 
and efficacy at 5-HT2A receptors (EC50 = 14.6 nM; Emax = 91%) compared to 5-HT2B (EC50 = 
36.7 nM; Emax = 73%) and 5-HT2C (EC50 = 183 nM; Emax = 73%) receptors. 
 ECPLA produced a significant increase in HTR counts over baseline levels in mice 
(F(3,20) = 14.92, p<0.0001).  Similar to other lysergamides (Halberstadt and Geyer 2013; Brandt 
et al. 2017a), ECPLA induced head twitches with a biphasic inverted-U-shaped dose-response 
function, with the peak response occurring at 0.3 mg/kg (p<0.01, Tukey’s test; see Figure 3).  
The ED50 of ECPLA is 130.2 µg/kg (317.2 nmol/kg) with a 95% CI of 87.5–193.7 µg/kg (213.2–
471.9 nmol/kg).  In comparison, LSD had an ED50 of 132.8 nmol/kg under equivalent conditions 
(Halberstadt and Geyer 2013), meaning that ECPLA induces the HTR with 42% of the molar 
potency of LSD. 
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 As shown in Figure 3, MIPLA (F(3,17) = 36.12, p<0.0001) and LAMPA (F(4,23)=14.44, 
p<0.0001) also induced the HTR in mice with biphasic dose-responses. The ED50 for MIPLA 
was 136.4 µg/kg (421.7 nmol/kg) with a 95% CI of 116.6–159.5 µg/kg (360.5–493.1 nmol/kg).  
The ED50 for LAMPA was 115.9 µg/kg (358.3 nmol/kg) with a 95% CI of 78.0–172.2 µg/kg 
(241.1–532.4 nmol/kg). 
 
DISCUSSION 
 
 The present investigation was conducted to examine the pharmacological properties of 
ECPLA, a novel analog of LSD.  Studies assessed the binding of ECPLA to monoamine 
receptors and its ability to activate 5-HT2 subtypes in vitro.  Additional experiments were 
conducted to determine whether ECPLA induces the HTR in mice. ECPLA bound to 5-HT 
receptors, adrenergic α2A and α2B receptors, and D2/3/4 dopamine receptors with moderately high 
affinity, which is reminiscent of the binding profile of LSD.  ECPLA was nearly a full agonist 
for Gq-mediated calcium flux at the 5-HT2A receptor but had lower efficacy and potency at 5-
HT2B and 5-HT2C receptors.  In addition, the effects of ECPLA in the head twitch paradigm 
suggest that it is capable of activating 5-HT2A receptors in vivo.  In summary, the fact that 
ECPLA is a 5-HT2A agonist with nanomolar affinity and produces HTRs in mice strongly 
suggests it will act as an LSD-like (hallucinogenic) agent in humans.   
 ECPLA and LSD have remarkably similar binding profiles at monoamine receptors.  
Replacing one of the two ethyl groups present in LSD with a cyclopropyl group apparently has 
little influence on its ability to interact with serotonergic, dopaminergic, adrenergic, or 
histaminergic receptors.  One notable difference between LSD and ECPLA is that the former 
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compound has moderate affinity for β1 (Ki = 140 nM) and β2 (Ki = 740 nM) receptors (Nichols et 
al. 2002) whereas the affinity of ECPLA for those receptors is negligible (i.e., <50% 
displacement at 10 µM).  Nevertheless, in humans, the concentration of LSD in cerebrospinal 
fluid (CSF) probably does not exceed 0.6–0.8 nM after a 200 µg p.o. dose (Dolder et al. 2015), 
so the interaction between LSD and β-adrenergic receptors is unlikely to contribute to its 
psychopharmacology.  Although the concentration of LSD in CSF is relatively low compared to 
its reported affinity for 5-HT2A (Ki = 13 nM; Nichols 2017), the competitive binding assays used 
to determine the Ki are likely to underestimate the affinity of LSD due to its receptor kinetics.  
LSD has a long residence time at the 5-HT2A receptor; reported t1/2 values range from 20 min 
(Bennett and Snyder 1975; Burris and Sanders-Bush 1992) to 138.6 min (Wacker et al 2017).  
Given the slow dissociation of LSD from 5-HT2A, binding may not reach equilibrium during 
competitive binding assays, resulting in an underestimation of affinity.  Indeed, when affinity is 
determined using association and dissociation assays, [3H]LSD binds to the 5-HT2A receptor with 
KD = 0.33 nM (Wacker et al. 2017), which is consistent with the concentration in CSF. 
 The binding of LSD to the 5-HT2A receptor is known to be highly sensitive to the steric 
and conformational properties of the amide substituent (Oberlender et al. 1992; Huang et al. 
1994; Monte et al. 1995; Nichols et al. 1996).  The conformation of the diethylamide moiety in 
LSD is optimal for binding because it interacts with a region of the 5-HT2A receptor that has a 
highly complementary structure (Wacker et al. 2017).  ECPLA and LSD exhibited similar 
affinities for [3H]ketanserin-labeled 5-HT2A sites, indicating the binding site can readily 
accommodate an amide substituent that is marginally bulkier than ethyl.  Although cyclopropyl 
substitution did not alter 5-HT2A binding affinity relative to LSD, a reduction of agonist potency 
at the 5-HT2A receptor was observed.  ECPLA activates the human 5-HT2A receptor (h5-HT2A) 
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with an EC50 of 14.6 nM.  According to Wacker et al. (2017), LSD activates h5-HT2A in the 
same expression system with an EC50 of 3.61 nM.  The difference in 5-HT2A agonist potency 
between LSD and ECPLA roughly parallels their potencies in the HTR assay, which is consistent 
with our previous finding that ED50 values in the HTR assay are correlated with potencies for 
inducing Ca2+ mobilization via the 5-HT2A receptor (Nichols et al. 2015).  Therefore, compared 
to 5-HT2A binding affinity, receptor activation may exhibit a greater sensitivity to changes in the 
steric bulk of the amide substituent.  In addition to increasing steric bulk, cyclopropyl 
substitution would also alter the conformational mobility of the amide side-chain.  Homology 
modeling suggest that the two ethyl groups in LSD adopt a trans conformation when bound to 
the 5-HT2A receptor (Wacker et al. 2017); the substituents in ECPLA may adopt a slightly 
different orientation, potentially reducing agonist potency.  
 The reduction in in vivo potency produced by replacing one of the N-ethyl groups in LSD 
with an N-cyclopropyl group closely mirrored the effect of N-isopropyl substitution observed 
previously with EIPLA.  According to Huang et al. (1994), EIPLA produced full substitution in 
rats trained to discriminate 0.08 mg/kg LSD but was only 36% as potent as the training drug.  A 
similar potency reduction (42%) occurred with ECPLA relative to LSD in the HTR assay.  
Although many hallucinogens have been tested in both mouse head twitch and rat drug 
discrimination (DD) studies, it is not clear whether a relationship exists between potencies in 
these paradigms, making it difficult to compare the relative behavioral potencies of EIPLA and 
ECPLA.  Nevertheless, according to our preliminary studies, there does appear to be a robust and 
highly significant correlation between rat DD- and mouse HTR-derived ED50 values for 
phenylalkylamine and tryptamine hallucinogens (Halberstadt et al., unpublished findings), 
demonstrating that potencies in the HTR and DD paradigms are likely closely related. 
Psychopharmacology, accepted 25 Sep 2018 
17 
 
 MIPLA, the N-methyl-N-isopropyl isomer of LSD, also induced head twitches in mice.  
On a molar basis, MIPLA was only slightly less potent than ECPLA in the HTR paradigm and 
has about a third of the potency of LSD.  Since MIPLA and ECPLA have nearly comparable 
potencies in mice, it appears that N-cyclopropyl vs. N-isopropyl substitution does not appreciably 
alter the behavioral pharmacology of lysergamides.  MIPLA was found to fully substitute for 
LSD in rats, with about half the potency of the training drug (Huang et al. 1994).  According to 
Shulgin, human subjects administered MIPLA at doses of 180–300 µg experienced LSD-like 
psychedelic effects, making it about two- to threefold less potent than LSD (Shulgin 2016).  
Hence, there is converging evidence that MIPLA also has behavioral effects comparable to LSD 
but with reduced potency.   
 The LSD isomer LAMPA induced head twitches in mice and was virtually equipotent 
with ECPLA and MIPLA.  Although LAMPA is reportedly less potent than LSD in humans 
(Abramson and Rolo 1967), few details have been published regarding the psychopharmacology 
of this compound.  Based on the HTR data, LAMPA is predicted to act as a hallucinogen in 
humans with approximately three-fold lower potency than LSD.      
 The pharmacological and behavioral properties of ECPLA are thus reminiscent of LSD 
and other lysergamide hallucinogens.  In this study, ECPLA acted as a potent and highly 
efficacious 5-HT2A agonist and induced head twitches in mice with only slightly lower potency 
than LSD.  These findings indicate that ECPLA is likely to produce hallucinogenic effects in 
humans, although clinical trials are ultimately necessary to understand the human 
psychopharmacology of ECPLA.  Given the pharmacology of ECPLA, it has the potential to be 
used in a manner similar to other lysergamide hallucinogens.  LSD is becoming an important tool 
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in clinical research and the possibility exists that ECPLA could also be used for similar research 
purposes.   
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Table 1.  Receptor binding data for N-ethyl-N-cyclopropyllysergamide (ECPLA). 
 
Receptor Speciesa Radioligand Ki (nM)b,c 
5-HT1A Human [3H]8-OH-DPAT       3.2 ± 0.5 (3) 
5-HT1B Human [3H]GR125743     42.3 ± 8.7 (3) 
5-HT1D Human [3H]GR125743     12.6 ± 1.9 (3) 
5-HT2A Human [3H]ketanserin     16.5 ± 6.0 (3) 
5-HT2B Human [3H]LSD       5.3 ± 1.3 (3) 
5-HT2C Human [3H]mesulergine     85.7 ± 31.2 (3) 
5-HT5A Human [3H]LSD       8.6 ± 4.2 (3) 
5-HT6 Human [3H]LSD     21.7 ± 4.4 (3) 
5-HT7 Human [3H]LSD     27.3 ± 11.5 (4) 
α1A Human [3H]prazosin > 10,000 
α1B Human [3H]prazosin 1954 ± 152 (3) 
α1D Human [3H]prazosin   > 10,000 
α2A Human [3H]rauwolscine     144 ± 64 (3) 
α2B Human [3H]rauwolscine     62.3 ± 15.1 (3) 
α2C Human [3H]rauwolscine   438 ± 118 (3) 
β1 Human (heartd) [125I]pindolol > 10,000e 
β2 Human [3H]CGP12177 > 10,000e  
β3 Human [3H]CGP12177 2415 ± 639 (4) 
D1 Human [3H]SCH23390   502 ± 122 (3) 
D2 Human [3H]N-methylspiperone   150 ± 32 (3) 
D3 Human [3H]N-methylspiperone   104 ± 29 (3) 
D4 Human [3H]N-methylspiperone     92.3 ± 11.9 (3) 
D5 Human [3H]SCH23390 1504 ± 386 (4) 
H1 Human [3H]pyrilamine > 10,000e 
H2 Human [3H]tiotidine   890 ± 137 (3) 
H3 Guinea pig [3H]α-methylhistamine > 10,000e 
H4 Human [3H]histamine > 10,000e 
aThe experiments were performed using cloned receptors from the species indicated. 
bMean ± SEM. 
cThe number of independent determinations (performed in triplicate) are listed in parentheses. 
dThe experiment was performed using tissues natively expressing the receptor. 
eIC50 > 10 µM in the primary binding assay. 
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Table 2.  Functional activity of N-ethyl-N-cyclopropyllysergamide (ECPLA) at 5-HT2 receptors. 
 
 
 
Receptor 
ECPLA 5-HT 
EC50, nM 
(pEC50 ± SEM) 
Emax 
% 5-HT 
EC50, nM 
(pEC50 ± SEM) 
Emax 
% 5-HT 
h5-HT2A 14.6 
(7.84 ± 0.04) 
91 ± 1 0.50 
(9.30 ± 0.04) 
100 
h5-HT2B 36.7 
(7.44 ± 0.06) 
73 ± 2 0.56 
(9.25 ± 0.03) 
100 
h5-HT2C 183 
(6.74 ± 0.09) 
73 ± 3 0.24 
(9.63 ± 0.07) 
100 
Data were acquired with HEK293 cells expressing either human 5-HT2A (h5-HT2A), human 5-
HT2B (h5-HT2B), or human 5-HT2C INI (h5-HT2C) receptors.  Data represent EC50 and Emax 
means and standard error of the mean (SEM) from two independent experiments performed in 
quadruplicate.  Emax is defined as percent 5-HT maximum response. 
 
 
 
Table 3.  Effect of lysergamides on the head twitch response (HTR). 
 
Compound Dose 
(mg/kg) 
N Duration 
(min) 
HTR Counts 
(Mean ± SEM) 
ED50, µg/kg 
(95% CI) 
ED50, nmol/kg 
(95% CI) 
ECPLAa 0 6 30 7.3 ± 1.7 130.2 317.2  
 0.1 7  17.7 ± 2.6 (87.5–193.7) (213.2–471.9) 
 0.3 5  34.6 ± 5.1 *   
 1 6  28.2 ± 2.6 *   
MIPLAb 0 5 30 6.2 ± 1.4 136.4 421.7 
 0.1 6  12.3 ± 1.1 (116.6–159.5) (360.5–493.1) 
 0.2 5  31.8 ± 1.9 *   
 0.4 5  26.6 ± 3.1 *   
LAMPAb 0 6 20 5.0 ± 1.0 115.9 358.3 
 0.1 5  15.8 ± 2.7 (78.0–172.2) (241.1–532.4) 
 0.3 6  31.0 ± 2.2 *   
 1 6  19.5 ± 3.2 *   
 3 5  7.4 ± 4.3   
ahemitartrate (2:1) salt; bfree base. *p<0.01 vs. vehicle control group (Tukey’s test). 
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FIGURE CAPTIONS 
 
 
 
 
Figure 1.  Chemical structures of lysergic acid diethylamide (LSD), N-ethyl-N-cyclopropyl lysergamide (ECPLA), 
N-methyl-N-isopropyl lysergamide (MIPLA), and N-methyl-N-propyl lysergamide (LAMPA). 
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Figure 2.  Agonist potencies of N-ethyl-N-cyclopropyl lysergamide (ECPLA) at 5-HT2 receptor subtypes.  
Concentration-response curves for ECPLA and dimethylsulfoxide (DMSO) vehicle are shown for human 5-HT2A, 5-
HT2B, and 5-HT2C receptors expressed in HEK293 cells.  Values are the mean ± SEM of two independent 
experiments performed in quadruplicate. 
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Figure 3.  Effect of N-ethyl-N-cyclopropyl lysergamide (ECPLA, top panel), N-methyl-N-isopropyl lysergamide 
(MIPLA, middle panel), and N-methyl-N-propyl lysergamide (LAMPA, bottom panel) on the head twitch response.  
Data are presented as group means ± SEM for the first 20-min of the test session (LAMPA) or the entire 30-min test 
session (ECPLA and MIPLA).  *p<0.01, significant difference from the vehicle control group (Tukey’s test). 
 
